Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints

Category Primary study
JournalJournal of Clinical Oncology
Year 2020
This article has no abstract
Epistemonikos ID: 3029edd1efedf12c63cae39047225798e1643cbb
First added on: Feb 11, 2025